Today in News History
On July 12, several notable moments in the history of News stand out. In 1950, Pakistan joins the International Monetary Fund and the International Bank. In 1953, Piyasvasti Amranand, Thai businessman and politician, Thai Minister of Energy was born. In 1955, Balaji Sadasivan, Singaporean neurosurgeon and politician, Singaporean Minister of Health (died 2010) was born. In 1956, Amitav Ghosh, Indian-American author and academic was born. In 1991, Mokhtar Dahari, Malaysian footballer and coach (born 1953) passed away. In 2004, Laurance Rockefeller, American financier and philanthropist (born 1910) passed away. In 2013, Emik Avakian, Iranian-American inventor (born 1923) passed away. In 2015, André Leysen, Belgian businessman (born 1927) passed away. In 2015, Satoru Iwata, Japanese game programmer and businessman (born 1959) passed away. In 2020, Marc Angelucci, American attorney and men's rights activist, Vice-president of the National Coalition for Men (born 1968) passed away. Together, these milestones provide historical context for today's news news and ongoing narratives.
Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal Manchanda
India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and consumer healthcare. While US FDA approvals for complex generics remain a challenge, innovation and contract manufacturing offer significant future profit pools. Experts anticipate biosimilars could generate substantial revenue, and despite a slow start, GLP-1 drugs show long-term promise. Sun Pharma is highlighted as a preferred domestic investment.
Narrative Intelligence Brief
This article was published by Economic Times, a source frequently categorized with a center bias based in India. Our narrative intelligence engine continuously monitors coverage from this outlet to track framing, bias, and rhetorical patterns. Our initial algorithmic scan of this specific piece did not flag high-confidence rhetorical techniques, suggesting a generally straightforward reporting style or neutral framing. By understanding the editorial perspective of Economic Times, readers can better contextualize the information presented and compare it across our broader media matrix to find the real narrative.
More from Economic Times
Analysis Methodology
This narrative analysis was generated using the CoDataLab Global Intelligence Engine. Our proprietary AI scans thousands of cross-border sources to identify sentiment patterns, framing techniques, and potential media bias. While AI provides the data-driven foundation, our objective is to empower readers with additional context beyond the standard headline.The content displayed above is a structured summary designed for rapid information processing. For the full original report, please visit the source outlet.More Coverage
Discussion
"cup semifinals"
Julian Alvarez's strike sends defending champion Argentina back to World Cup semifinals
World Cup 2026 Saturday takeaways: Jude Bellingham shines; Argentina takes advantage of Swiss flop
2026 World Cup Semifinal Odds: France, Argentina Favored In Final Four Tilts
How other outlets are covering this story
Compare narratives across 4 related reports from 4 sources. Real Narrative News aggregates the coverage spectrum so you can see who emphasises what — bias tags reflect the outlet, not the story.
Coverage bias distribution
4 sources
Left 25%
Center 0%
Right 75%
Seeking Alpha
· Jun 25, 2026
Crinetics Pharmaceuticals: 'Buy' On Palsonify Market Expansion And Atumelnant Advancements
Crinetics Pharmaceuticals: 'Buy' On Palsonify Market Expansion And Atumelnant Advancements
The Hindu BusinessLine
· Jul 8, 2026
Indian biotechs are scaling abroad before coming home
Global-first strategy helps Indian biotech startups fund research and accelerate growth
The Motley Fool
· Jul 5, 2026
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?
The company recently wowed investors with clinical trial results.
India Today
· Jul 3, 2026
Profits over health? Inside story of India's U-turn on carcinogenic fungicide Thiram
Profits over health? Inside story of India's U-turn on carcinogenic fungicide Thiram
Topics:
Related coverage for "Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal Manchanda ": Seeking Alpha — Crinetics Pharmaceuticals: 'Buy' On Palsonify Market Expansion And Atumelnant Advancements. The Hindu BusinessLine — Indian biotechs are scaling abroad before coming home. The Motley Fool — Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?. India Today — Profits over health? Inside story of India's U-turn on carcinogenic fungicide Thiram